A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus

Inclusion Criteria: * Patients with Type 2 diabetes mellitus with inadequate glycemic control on diet and exercise. HbA1c \>= 7% and \<=10%. * Patient either has not been previously treated with antihyperglycemic medication or has been treated for \<30 days since diagnosis and has received less than 3 consecutive doses or 7 non-consecutive doses in the last 30 days. * C-peptide \> 1.0 ng/ml * Body Mass Index \<= 40 kg/m2 * Serum creatinine \< 1.5 mg/dL for men or \< 1.4 mg/dL for women. * No overt proteinuria (microalbumin/creatinine ratio must be \<300 mg/g Exclusion Criteria: * Unstable renal disease * Patients with significant liver disease including chronic active hepatitis * Within the last 6 months has had any of the following cardiovascular event: myocardial infarction, unstable angina, unstable CHF,NYHA Class III or IV CHF, TIA, unstable arrhythmia or cardiac revascularization surgery. * Subjects with clinically significant anemia